1. Metabolic Partnering Terms and Agreements
Report Details:
Published:September 2012
No. of Pages: 448
Price: Single User License – US$2695
This report provides comprehensive understanding and unprecedented access to the metabolic
partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter
metabolic partnering deals. The majority of deals are discovery or development stage whereby the
licensee obtains a right or an option right to license the licensors metabolic technology. These
deals tend to be multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered – contract documents
provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual metabolic deals and contract
documents as submitted to the Securities Exchange Commission by companies and their
partners. Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a significant
impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of metabolic dealmaking and business
activities. Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in metabolic dealmaking since 2007 covering trends
by year, deal type, stage of development, technology type and therapeutic indication. In addition
the chapter includes an analysis of financial deal terms by stage at signing covering headline
value, upfront payment, milestone payments and royalty rates. Analysis includes median values
and distribution of values for each stage of development.
Chapter 3 provides a review of the leading metabolic deals since 2007. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief
summary followed by a comprehensive listing of metabolic deals, as well as contract documents
available in the public domain. Where available, each deal title links via Weblink to an online

2. version of the actual contract document, providing easy access to each contract document on
demand.
Chapter 5 provides comprehensive access to all metabolic deals since 2007 where a deal contract
is available, providing the user with direct access to contracts as filed with the SEC regulatory
authorities. Each deal title links via Weblink to an online version of the deal record contract
document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all metabolic partnering deals signed and
announced since 2007. The chapter is organized by specific metabolic therapy focus. Each deal
title links via Weblink to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all metabolic partnering
deals signed and announced since 2007. The appendices are organized by company A-Z, stage
of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in
metabolic partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about
partnering in the research, development and commercialization of metabolic technologies and
products.
Metabolic Partnering Terms and Agreements provides the reader with the following key
benefits:
•In-depth understanding of metabolic deal trends since 2007
•Access metabolic deal headline, upfront, milestone and royalty data
•Research hundreds of actual contracts between metabolic partner companies
•Comprehensive access to over 1,000 links to actual metabolic deals entered into by the world’s
biopharma companies
•Indepth review of metabolic deals entered into by the leading fifty bigpharma companies
•Benchmark the key deal terms companies have agreed in previous deals
•Identify key terms under which companies partner metabolic opportunities
•Uncover companies actively partnering metabolic opportunities
Get your copy of this report @
http://www.reportsnreports.com/reports/191581-metabolic-partnering-terms-and-agreements.html
Major points covered in Table of Contents of this report include
Table of Contents
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in metabolic dealmaking
2.1. Introduction
2.2. Metabolic partnering over the years

3. 2.3. Bigpharma metabolic dealmaking activity
2.4. Bigpharma not active in metabolic
2.5. Metabolic partnering by deal type
2.6. Metabolic partnering by industry sector
2.7. Metabolic partnering by stage of development
2.8. Metabolic partnering by technology type
2.9. Metabolic partnering by metabolic indication
2.10. Average deal terms for metabolic diseases
2.10.1 Metabolic headline values
2.10.2 Metabolic upfront payments
2.10.3 Metabolic milestone payments
2.10.4 Metabolic royalty rates
Chapter 3 – Leading metabolic deals
3.1. Introduction
3.2. Top metabolic deals by value
3.3. Top metabolic deals involving bigpharma
Chapter 4 – Bigpharma metabolic deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma metabolic partnering company profiles
Abbott
Actavis
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson

4. Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Pfizer Animal Health
Pfizer Nutrition
Roche
Sanofi
Servier
Shire
Takeda
Teva
Valeant
Watson
Chapter 5 – Metabolic partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Licensing
Litigation
Loan
Manufacturing
Marketing

5. Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
5.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
Formulation
5.4. By technology type
Analysis
Animal models
Assays
Biological compounds
Biomarkers
Biomaterials
Blood products
Cell culture
Cell therapy
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Facilities
Gene therapy
Genomics
Imaging
Implant

6. In vitro models
Nanotechnology
Natural product
Oligonucleotide
Orphan drug
Packaging
Peptides
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Toxicity
Vaccines
Chapter 6 – Metabolic dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Metabolic
Acromegaly
Addison's disease
Cirrhosis
Cushing's syndrome
Diabetes
Fatty liver
Gallstones
Growth hormone disorders
Hyperthyroidism
Hypogonadism
Hypothyroidism
Phenylketonuria
Liver disease
Lysosomal storage disorders
Nutrition and vitamins
Short stature
Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
Thyroid disease

7. Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
Appendices
Appendix 1 – Directory of metabolic deals by company A-Z 2007-2012
Appendix 2 – Directory of metabolic deals by deal type 2007-2012
Appendix 3 – Directory of metabolic deals by stage of development 2007-2012
Appendix 4 – Directory of metabolic deals by technology type 2007-2012
Appendix 5 – Deal type definitions
List of Tables & figures
Figure 1: Metabolic partnering since 2007
Figure 2: Bigpharma – top 50 – metabolic deals 2007 to 2012
Figure 3: Bigpharma metabolic deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in metabolic 2007-2012
Figure 5: Metabolic partnering by deal type since 2007
Figure 6: Metabolic partnering by industry sector since 2007
Figure 7: Metabolic partnering by stage of development since 2007
Figure 8: Metabolic partnering by technology type since 2007
Figure 9: Metabolic partnering by metabolic target since 2007
Figure 10: Metabolic deals with a headline value
Figure 11: Metabolic deal headline value distribution, US$million – discovery stage
Figure 12: Metabolic deal headline value distribution, US$million – preclinical stage
Figure 13: Metabolic deal headline value distribution, US$million – phase I stage
Figure 14: Metabolic deal headline value distribution, US$million – phase II stage
Figure 15: Metabolic deal headline value distribution, US$million – phase III stage
Figure 16: Metabolic deal headline value distribution, US$million – regulatory stage
Figure 17: Metabolic deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2012
Figure 19 Metabolic deals with upfront payment values
Figure 20: Metabolic deal upfront payment distribution, US$million – discovery stage
Figure 21: Metabolic deal upfront payment distribution, US$million – preclinical stage
Figure 22: Metabolic deal upfront payment distribution, US$million – phase I stage
Figure 23: Metabolic deal upfront payment distribution, US$million – phase II stage
Figure 24: Metabolic deal upfront payment distribution, US$million – phase III stage
Figure 25: Metabolic deal upfront payment distribution, US$million – regulatory stage

8. Figure 26: Metabolic deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2012
Figure 28: Metabolic deals with milestone payments
Figure 29: Metabolic deal milestone distribution, US$million – discovery stage
Figure 30: Metabolic deal milestone distribution, US$million – preclinical stage
Figure 31: Metabolic deal milestone distribution, US$million – phase I stage
Figure 32: Metabolic deal milestone distribution, US$million – phase II stage
Figure 33: Metabolic deal milestone distribution, US$million – phase III stage
Figure 34: Metabolic deal milestone distribution, US$million – regulatory stage
Figure 35: Metabolic deal milestone distribution, US$million – marketed stage
Figure 36: Metabolic deals with royalty rates, %
Figure 37: Metabolic deal royalty rate distribution, US$million – discovery stage
Figure 38: Metabolic deal royalty rate distribution, US$million – preclinical stage
Figure 39: Metabolic deal royalty rate distribution, US$million – phase I stage
Figure 40: Metabolic deal royalty rate distribution, US$million – phase II stage
Figure 41: Metabolic deal royalty rate distribution, US$million – phase III stage
Figure 42: Metabolic deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2012
Figure 45: Top metabolic deals by value since 2007
Figure 46: Top metabolic deals signed by bigpharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Contact: sales@reportsandreports.com for more information.